Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial
The Lancet Regional Health - Western Pacific (2022) - Comments
pubmed: 35602004  doi: 10.1016/j.lanwpc.2022.100474  issn: 2666-6065 

Thuy P. Nguyen, Quyet Do, Lan T. Phan, Duc V. Dinh, Hiep Khong, Luong V. Hoang, Thuong V. Nguyen, Hung N. Pham, Men V. Chu, Toan T. Nguyen, Quang D. Pham, Tri M. Le, Tuyen N.T. Trang, Thanh T. Dinh, Thuong V. Vo, Thao T. Vu, Quynh B.P. Nguyen, Vuong T. Phan, Luong V. Nguyen, Giang T. Nguyen